Berg Lab
The Berg Lab focuses on the discovery of novel biomarkers for clinical diagnostic applications. A main project is the development of a test for carbamylated albumin as a clinical tool for patients with kidney disease, a “hemoglobin A1c for uremia.” Dr. Berg has also worked to understand the pathophysiology of preeclampsia and develop and validate FDA-approved tests for predicting the risk of development of preeclampsia in mothers during their 3rd trimester and developed assays for bioavailable 25-hydroxyvitamin seeking to prove that bioavailable 25-hydroxyvitamin D is a better indicator of vitamin D sufficiency than tests for total 25-hydroxyvitamin D.
Breakthrough Research
- Protein carbamylation and the pathophysiology of uremic cardiomyopathy in chronic kidney disease
- Pathophysiology and diagnostic testing in preeclampsia
- The physiology of Vitamin D and Vitamin D binding protein
- Role of nicotinamide adenine dinucleotide in the pathophysiology of kidney disease
Laboratory Team
Learn more about the scientists, faculty members, investigators, and other healthcare professionals of the Berg Lab, whose dedicated efforts lead to groundbreaking discoveries.
Job Opportunities
We are actively recruiting students and postdocs to be our colleagues and expand lab knowledge and expertise to make important breakthroughs.
Collaborations
The Berg Lab collaborates with a wide range of investigators within Cedars-Sinai and institutions around the world.
- Karumanchi Lab